Drug Trial Radar · NCT01033071
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
Last checked: Nov 19, 2026Latest source record: Feb 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,071
Actual
Start
Jan 2010
Primary completion
Oct 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil plus chlorthalidone, once daily (QD), to olmesartan medoxomil plus hydrochlorothiazide in participants with moderate to severe hypertension.
Conditions
- Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidoneDrug
Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks. Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks. Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.
Azilsartan medoxomil and chlorthalidoneDrug
Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks. Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks. Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.
Olmesartan medoxomil and hydrochlorothiazideDrug
Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks. Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks. Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.Time frame: Baseline and Week 12.
Locations
94 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Gulf Shores, Alabama
Site not named
Litchfield Park, Arizona
Site not named
Mesa, Arizona
Site not named
Scottsdale, Arizona
Site not named
Tucson, Arizona
Site not named
Buena Park, California
Site not named
Carmichael, California
Site not named
Greenbrae, California
Site not named
Irvine, California
Site not named
Paramount, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Spring Valley, California
Site not named
Wildomar, California
Site not named
Colorado Springs, Colorado
Site not named
Milford, Connecticut
Site not named
Waterbury, Connecticut
Site not named
Newark, Delaware
Site not named
Aventura, Florida
Site not named
Clearwater, Florida
Site not named
DeLand, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Miami, Florida
Site not named
Ocala, Florida
Site not named
Plant City, Florida
Site not named
Tallahassee, Florida
Site not named
Tampa, Florida
Site not named
West Palm Beach, Florida
Site not named
Winter Haven, Florida
Site not named
Dunwoody, Georgia
Site not named
Roswell, Georgia
Site not named
Suwanee, Georgia
Site not named
Chicago, Illinois
Site not named
Melrose Park, Illinois
Site not named
Naperville, Illinois
Site not named
Avon, Indiana
Site not named
Indianapolis, Indiana
Site not named
Valparaiso, Indiana
Site not named
Crestview Hills, Kentucky
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.